A case of antiprogrammed death-ligand 1 antibody-induced multisystem immune-related adverse events with pancreatitis and steroid-resistant sclerosing cholangitis
A case of antiprogrammed death-ligand 1 antibody-induced multisystem immune-related adverse events with pancreatitis and steroid-resistant sclerosing cholangitis
复制标题
抗程序性死亡配体1抗体诱发胰腺炎和类固醇抵抗性硬化性胆管炎多系统免疫相关不良事件一例
DOI：
10.1111/1751-2980.13122
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Ishigami M.
中科院分区：
文献类型：
--
作者：
Yamamoto T;Ito T（Corresponding）;Mizuno K;Shinya Y;Yamamoto K;Imai N;Ishizu Y;Honda T;Kawashima H;Matsui T;Hase T;Hashimoto N;Ishigami M.
免疫检查点抑制剂（ICI）已被用于多种癌症;然而，这些治疗可能会导致免疫相关不良事件（irAE）。1根据我们之前的研究，免疫相关性肝损伤（liver-irAE）是一种相对罕见的不良事件，2级和≥ 3级肝损伤的发生率分别为2.7%和5.3%。irSC的各种影像学表现可能受到发病时间、严重程度和类固醇治疗的影响;因此，即使在类固醇治疗改善了肝损伤后，我们也需要密切监测irSC患者。第一次肝损伤时的腹部计算机断层扫描（CT）的轴向图像显示胰腺轻度肿胀，无肝转移。我们怀疑免疫相关的肝损伤，包括胆管炎和胰腺炎，由于ICI，并进行了肝活检。[摘自文章]
Immune checkpoint inhibitors (ICIs) have been indicated for several cancers; however, these treatments may cause immune-related adverse events (irAE). 1 According to our previous study, immune-related liver injury (liver-irAE) is a relatively rare adverse event, with incidence rates of 2.7% and 5.3% for grades 2 and >= 3 liver injury, respectively. The diverse imaging findings of irSC can be influenced by the time of onset, severity, and steroid therapy; thus, we need to closely monitor patients with irSC even after liver injury has improved with steroid treatment. A, Axial image of contrast-enhanced abdominal computed tomography (CT) at the time of the first liver injury showing mild swelling of the pancreas, with no liver metastasis. We suspected immune-related liver injury, including cholangitis and pancreatitis, due to ICIs, and performed a liver biopsy.[Extracted from the article]